Revolution Medicines has been granted a patent for compounds capable of modulating biological processes by binding to presenter and target proteins. The invention involves macrocyclic compounds that selectively bind and modulate the activity of the target protein CEP250 through protein-compound and protein-protein interactions. GlobalData’s report on Revolution Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revolution Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Revolution Medicines's grant share as of May 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11987590B2) discloses a macrocyclic compound or its pharmaceutically acceptable salt, comprising a target protein interacting moiety and a presenter protein binding moiety. The compound forms a complex with a presenter protein that specifically binds to the target protein, with a significantly higher affinity than when each component binds individually. The patent covers various structures for the target protein interacting moiety and presenter protein binding moiety, allowing for customization and optimization of the compound's binding properties.
Furthermore, the patent includes claims related to pharmaceutical compositions, methods of modulating target proteins, treating cancer, ciliopathy, and infections, as well as inhibiting prolyl isomerase activity. The disclosed compound can be used in various therapeutic applications, demonstrating its potential in the field of medicine. Additionally, the patent describes a tripartite complex involving a target protein, a presenter protein/compound complex, and the compound itself, showcasing the versatility and specificity of the disclosed macrocyclic compound in interacting with proteins. Overall, the patent provides a comprehensive framework for the development and application of the disclosed compound in various biomedical contexts, highlighting its potential for therapeutic interventions and protein modulation.
To know more about GlobalData’s detailed insights on Revolution Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
